{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:40:03Z","timestamp":1749940803278,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40273-025-01497-w","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T16:00:34Z","timestamp":1745942434000},"page":"711-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness Analysis Methods Used in Evaluations of Treatment for Cystic Fibrosis: A Scoping Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-4690","authenticated-orcid":false,"given":"Dominique","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0977-7257","authenticated-orcid":false,"given":"David C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8547-1810","authenticated-orcid":false,"given":"Eberechukwu","family":"Onukwugha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-5780","authenticated-orcid":false,"suffix":"II","given":"T. Joseph","family":"Mattingly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"1","key":"1497_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65\u2013124.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"1497_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","volume":"44","author":"LT Clark","year":"2019","unstructured":"Clark LT, Watkins L, Pi\u00f1a IL, Elmer M, Akinboboye O, Gorham M, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44(5):148\u201372.","journal-title":"Curr Probl Cardiol"},{"unstructured":"Understanding changes in life expectancy | Cystic Fibrosis Foundation [Internet]. [cited 2024 Aug 6]. https:\/\/www.cff.org\/managing-cf\/understanding-changes-life-expectancy.","key":"1497_CR3"},{"unstructured":"Our history | Cystic Fibrosis Foundation [Internet]. [cited 2024 Nov 25]. https:\/\/www.cff.org\/about-us\/our-history.","key":"1497_CR4"},{"doi-asserted-by":"publisher","unstructured":"Cheema ZM, Gomez LC, Johnson N, Laflamme OD, Rabin HR, Steele K, Wallenburg J, Leong J, Cheng SY, Quon BS, Stephenson AL, Wranik WD, Sadatsafavi M, Stanojevic S. Measuring the burden of cystic fibrosis: a scoping review. J Cyst fibros off J Eur Cyst Fibros Soc. 2024;23(5):823\u2013830. https:\/\/doi.org\/10.1016\/j.jcf.2023.11.014","key":"1497_CR5","DOI":"10.1016\/j.jcf.2023.11.014"},{"issue":"12","key":"1497_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/ppul.24178","volume":"53","author":"SD Grosse","year":"2018","unstructured":"Grosse SD, Do TQN, Vu M, Feng LB, Berry JG, Sawicki GS. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010\u20132016. Pediatr Pulmonol. 2018;53(12):1611\u20138.","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"1497_CR7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","volume":"21","author":"J Guo","year":"2022","unstructured":"Guo J, Wang J, Zhang J, Fortunak J, Hill A. Current prices versus minimum costs of production for CFTR modulators. J Cyst Fibros. 2022;21(5):866\u201372.","journal-title":"J Cyst Fibros"},{"issue":"15","key":"1497_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12913-015-1061-3","volume":"28","author":"A Angelis","year":"2015","unstructured":"Angelis A, Kanavos P, L\u00f3pez-Bastida J, Linertov\u00e1 R, Nicod E, Serrano-Aguilar P. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv Res. 2015;28(15):428.","journal-title":"BMC Health Serv Res"},{"key":"1497_CR9","doi-asserted-by":"publisher","first-page":"175346662210864","DOI":"10.1177\/17534666221086416","volume":"16","author":"C Daly","year":"2022","unstructured":"Daly C, Ruane P, O\u2019Reilly K, Longworth L, Vega-Hernandez G. Caregiver burden in cystic fibrosis: a systematic literature review. Ther Adv Respir Dis. 2022;16:17534666221086416.","journal-title":"Ther Adv Respir Dis"},{"issue":"2","key":"1497_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40258-015-0211-4","volume":"14","author":"IL Hollin","year":"2016","unstructured":"Hollin IL, Robinson KA. A scoping review of healthcare costs for patients with cystic fibrosis. Appl Health Econ Health Policy. 2016;14(2):151\u20139.","journal-title":"Appl Health Econ Health Policy"},{"issue":"10","key":"1497_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"10","key":"1497_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","volume":"38","author":"DD Kim","year":"2020","unstructured":"Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974\u20132018. Pharmacoeconomics. 2020;38(10):1135\u201345.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1497_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"1497_CR14","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1183\/13993003.01444-2015","volume":"47","author":"P Dilokthornsakul","year":"2016","unstructured":"Dilokthornsakul P, Hansen RN, Campbell JD. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation. Eur Respir J. 2016;47(6):1697\u2013705.","journal-title":"Eur Respir J"},{"issue":"1","key":"1497_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1017\/S0266462303000072","volume":"19","author":"R Grieve","year":"2003","unstructured":"Grieve R, Thompson S, Normand C, Suri R, Bush A, Wallis C. A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. Int J Technol Assess Health Care. 2003;19(1):71\u20139.","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"1497_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/21645515.2016.1235670","volume":"13","author":"AA McGirr","year":"2017","unstructured":"McGirr AA, Schwartz KL, Allen U, Solomon M, Sander B. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: a decision analysis model. Hum Vaccines Immunother. 2017;13(3):599\u2013606.","journal-title":"Hum Vaccines Immunother"},{"issue":"8","key":"1497_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40261-017-0537-9","volume":"37","author":"S Panguluri","year":"2017","unstructured":"Panguluri S, Gunda P, Debonnett L, Hamed K. Economic evaluation of tobramycin inhalation powder for the treatment of chronic pulmonary pseudomonas aeruginosa infection in patients with cystic fibrosis. Clin Drug Investig. 2017;37(8):795\u2013805.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"1497_CR18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1513\/AnnalsATS.201312-453OC","volume":"12","author":"MS Schechter","year":"2015","unstructured":"Schechter MS, Trueman D, Farquharson R, Higuchi K, Daines CL. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation. Ann Am Thorac Soc. 2015;12(7):1030\u20138.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"1497_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-018-0914-3","volume":"13","author":"D Sharma","year":"2018","unstructured":"Sharma D, Xing S, Hung YT, Caskey RN, Dowell ML, Touchette DR. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States. Orphanet J Rare Dis. 2018;13(1):172.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1497_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40273-013-0122-x","volume":"32","author":"P Tappenden","year":"2014","unstructured":"Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C, et al. The cost effectiveness of dry powder antibiotics for the treatment of pseudomonas aeruginosa in patients with cystic fibrosis. Pharmacoeconomics. 2014;32(2):159\u201372.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1497_CR21","first-page":"276","volume":"27","author":"JA Tice","year":"2021","unstructured":"Tice JA, Kuntz KM, Wherry K, Seidner M, Rind DM, Pearson SD. The effectiveness and value of novel treatments for cystic fibrosis: a summary from the Institute for Clinical and Economic Review\u2019s California Technology Assessment Forum. J Manag Care Spec Pharm. 2021;27(2):276\u201380.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"1497_CR22","first-page":"987","volume":"24","author":"P Vadagam","year":"2018","unstructured":"Vadagam P, Kamal KM, Covvey JR, Giannetti V, Mukherjee K. Cost-effectiveness and budget impact of lumacaftor\/ivacaftor in the treatment of cystic fibrosis. J Manag Care Spec Pharm. 2018;24(10):987\u201397.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1497_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40273-019-00767-8","volume":"37","author":"E Warren","year":"2019","unstructured":"Warren E, Morgan K, Toward TJ, Schwenkglenks M, Leadbetter J. Cost effectiveness of inhaled mannitol (Bronchitol\u00ae) in patients with cystic fibrosis. Pharmacoeconomics. 2019;37(3):435\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1497_CR24","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jval.2020.05.016","volume":"23","author":"K Wherry","year":"2020","unstructured":"Wherry K, Williamson I, Chapman RH, Kuntz KM. Cost-effectiveness of ivacaftor therapy for treatment of cystic fibrosis patients with the G551D gating mutation. Value Health J Int Soc Pharmacoecon Outcomes Res. 2020;23(10):1332\u20139.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"6","key":"1497_CR25","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1542\/peds.103.6.e72","volume":"103","author":"TA Lieu","year":"1999","unstructured":"Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics. 1999;103(6):e72\u2013e72.","journal-title":"Pediatrics"},{"issue":"5","key":"1497_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4103\/IJPSYM.IJPSYM_334_18","volume":"40","author":"C Andrade","year":"2018","unstructured":"Andrade C. Internal, external, and ecological validity in research design, conduct, and evaluation. Indian J Psychol Med. 2018;40(5):498\u20139. https:\/\/doi.org\/10.4103\/IJPSYM.IJPSYM_334_18.","journal-title":"Indian J Psychol Med"},{"doi-asserted-by":"publisher","unstructured":"Marshall LZ, Espinosa R, Starner CI, Gleason PP. Real-world outcomes and direct care cost before and after elexacaftor\/tezacaftor\/ivacaftor initiation in commercially insured members with cystic fibrosis. J Manag Care Spec Pharm. 2023;29(6):599\u2013606. https:\/\/doi.org\/10.18553\/jmcp.2023.29.6.599.","key":"1497_CR27","DOI":"10.18553\/jmcp.2023.29.6.599"},{"issue":"7","key":"1497_CR28","first-page":"721","volume":"28","author":"S Smith","year":"2022","unstructured":"Smith S, Borchardt M. Analyzing the use and impact of elexacaftor\/tezacaftor\/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population. J Manag Care Spec Pharm. 2022;28(7):721\u201331.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"1497_CR29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jcf.2021.08.014","volume":"21","author":"E Granger","year":"2022","unstructured":"Granger E, Davies G, Keogh RH. Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor? J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21(2):316\u201322.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"1","key":"1497_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcf.2024.08.008","volume":"24","author":"AH Gifford","year":"2025","unstructured":"Gifford AH, Odem-Davis K, Kloster M, O\u2019Sullivan BP, Omlor GJ, Millard SL, et al. Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial. J Cyst Fibros. 2025;24(1):91\u20137.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"1497_CR31","first-page":"26","volume":"30","author":"LS Gold","year":"2024","unstructured":"Gold LS, Hansen RN, Mayer-Hamblett N, Nichols DP, Gifford AH, Kloster M, et al. The cost of simplifying treatments for cystic fibrosis: implications of the SIMPLIFY trial. J Manag Care Spec Pharm. 2024;30(1):26\u201333.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"1497_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.3804","volume":"4","author":"TJ Mattingly","year":"2023","unstructured":"Mattingly TJ, Hyman DA, Bai G. Pharmacy benefit managers: history, business practices, economics, and policy. JAMA Health Forum. 2023;4(11): e233804.","journal-title":"JAMA Health Forum"},{"issue":"6","key":"1497_CR33","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jval.2017.06.013","volume":"21","author":"J Levy","year":"2018","unstructured":"Levy J, Rosenberg M, Vanness D. A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses. Value Health. 2018;21(6):677\u201384.","journal-title":"Value Health"},{"issue":"9","key":"1497_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40273-018-0667-9","volume":"36","author":"TJ Mattingly","year":"2018","unstructured":"Mattingly TJ, Levy JF, Slejko JF, Onwudiwe NC, Perfetto EM. Estimating drug costs: how do manufacturer net prices compare with other common US price references? Pharmacoeconomics. 2018;36(9):1093\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1497_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0626","volume":"2","author":"WB Feldman","year":"2021","unstructured":"Feldman WB, Rome BN, Raimond VC, Gagne JJ, Kesselheim AS. Estimating rebates and other discounts received by Medicare part D. JAMA Health Forum. 2021;2(6): e210626.","journal-title":"JAMA Health Forum."},{"unstructured":"SEC filings | Vertex Pharmaceuticals [Internet]. 2024 [cited 2025 Jan 4]. https:\/\/investors.vrtx.com\/financial-information\/sec-filings.","key":"1497_CR36"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01497-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01497-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01497-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:01:40Z","timestamp":1749938500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01497-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01497-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"3 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.J.M. reports research support from the Alliance of Compounding Pharmacy (APC), the US Food and Drug Administration, and National Institute on Minority Health and Health Disparities, as well as consulting fees from Arnold Ventures, PCMA, and PhRMA unrelated to this manuscript. E.O. reports research support from BeiGene, Ltd. and Organon & Co., as well as consulting fees from PhRMA Foundation and The Center for Innovation and Value Research, unrelated to this manuscript. D.S. and D.C.Y. report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Conceptualization\u2014all authors; data curation\u2014DS and TJM; formal analysis, funding acquisition, investigation, and methodology\u2014DS and TJM; project administration, resources, and software\u2014DS and TJM; supervision\u2014all authors; validation, visualization, and roles\/writing\u2014original draft\u2014DS and TJM; and writing\u2014review and editing\u2014all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"CRediT Roles"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data generated and\/or analyzed for this study are available in the supplementary material.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}